Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$498.25 USD
-6.91 (-1.37%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $498.28 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$498.25 USD
-6.91 (-1.37%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $498.28 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
Integer Holdings (ITGR) Q3 Earnings Beat, 2022 View Lowered
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut
by Zacks Equity Research
DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.
Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
LabCorp (LH) Misses Q3 Earnings Estimates, Updates Guidance
by Zacks Equity Research
LabCorp's (LH) organic revenues decline significantly, mainly due to major decrease in COVID-19 PCR and antibody testing sales.
Merit Medical (MMSI) Q3 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in both its segments and the majority of product categories within its Cardiovascular unit.
Integra's (IART) Q3 Earnings Top, Gross Margin Declines
by Zacks Equity Research
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
Align Technology (ALGN) Q3 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The volatility surrounding inflationary pressure, weaker consumer confidence and the lingering impacts of COVID-19 shutdowns continue to pose challenges for Align Technology (ALGN).
CONMED (CNMD) Down on In-Line Q3 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings reflect strong segmental performance. Unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
The Zacks Analyst Blog Highlights The Home Depot, Elevance Health, BP, Gilead Sciences and ServiceNow
by Zacks Equity Research
The Home Depot, Elevance Health, BP, Gilead Sciences and ServiceNow are part of the Zacks top Analyst Blog.
Elevance Health, Inc. (ELV) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much a $1000 Investment in Elevance Health Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
Top Stock Reports for The Home Depot, Elevance Health & BP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Elevance Health Inc. (ELV) and BP p.l.c. (BP).
Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust demand for Thermo Fisher's (TMO) laboratory products and biopharma services buoys optimism. However, lower Life Sciences Solutions segment revenues in the third quarter disappoint.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Ideas feature highlights: Elevance Health, McKesson and Humana
by Zacks Equity Research
Elevance Health, McKesson and Humana are part of Zacks Investment Ideas article.
Centene (CNC) Q3 Earnings Top on Medicaid Arm, Revenues Rise Y/Y
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect solid membership growth within its Medicaid and Medicare businesses. Management currently expects adjusted EPS within $5.65-$5.75 for 2022.
3 Top-Ranked Medical Stocks Lapping the S&P 500
by Derek Lewis
All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.
HCA Healthcare (HCA) Q3 Earnings Beat, Revenues Decline Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results reflect a slight dip in expenses but lower revenues resulting from the havoc wreaked by Hurricane Ian on its Florida facilities.
Here is Why Growth Investors Should Buy Elevance Health (ELV) Now
by Zacks Equity Research
Elevance Health (ELV) could produce exceptional returns because of its solid growth attributes.
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Company News for Oct 20, 2022
by Zacks Equity Research
Companies in The News Are: TRV,ALLY,BMI,ELV
Elevance Health (ELV) Beats on Q3 Earnings, Ups '22 EPS View
by Zacks Equity Research
Elevance Health (ELV) is witnessing rapid growth in medical enrollment and expects to keep doing so.
Elevance Health (ELV) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.06% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.